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The literature on the relationship between breast cancer mortality and postmenopausal oestrogen and combined oestrogen/
progestin therapy is seemingly contradictory. This study explored survival after exposure to oestrogen or oestrogen plus progestin at
or in the year prior to breast cancer diagnosis. Information on patients first diagnosed with invasive breast cancer between 1993 and
1998 was linked with outpatient pharmacy data from 1992 to 2000. Patients were classified according to use of oestrogen alone or
oestrogen plus progestin at or in the year prior to diagnosis. Compared to nonusers, and adjusting for age at diagnosis, race/ethnicity,
tumour size and grade, oestrogen receptor status, surgery status, and chemotherapy and hormone therapy for breast cancer
treatment, oestrogen plus progestin users had lower all-cause mortality (stage I hazard ratio (HR)¼0.69, 95% confidence interval
(CI)¼0.48–0.99; stage II HR¼0.53, 95% CI¼0.39–0.72) and breast cancer mortality (stage I HR¼0.52, 95% CI¼0.26–1.04;
stage II HR¼0.69, 95% CI¼0.48–0.98). Oestrogen users experienced little or no survival benefit for all-cause mortality (stage I
HR¼1.04, 95% CI¼0.77–1.42; stage II HR¼0.86, 95% CI¼0.65–1.14) or breast cancer mortality (stage I HR¼1.23, 95% CI
0.72–2.10; stage II HR¼1.01, 95% CI 0.72–1.41). Our findings suggest, relative to nonusers, a lower risk of death from all causes and
from breast cancer in patients who were diagnosed with breast cancer while exposed to oestrogen plus progestin, but not in patients
exposed to oestrogen only.
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Studies have consistently reported a reduced risk of all-cause
mortality in hormone users vs nonusers (Hunt et al, 1990;
Henderson et al, 1991; Sturgeon et al, 1995; Ettinger et al, 1996;
Sellers et al, 1997; Grodstein et al, 1997). However, the literature on
the relationship between breast cancer mortality and postmeno-
pausal oestrogen and combined oestrogen/progestin therapy is
confusing and seemingly contradictory (Bergkvist et al, 1989; Hunt
et al, 1990; Henderson et al, 1991; Colditz et al, 1995; Sturgeon
et al, 1995; Persson et al, 1996; Willis et al, 1996; Grodstein et al,
1997; Sellers et al, 1997; Sourander et al, 1998; Schairer et al, 1999;
Jernstrom et al, 1999; Beral, 2003). A systematic review of
postmenopausal hormone replacement therapy and the risk of
death from breast cancer found that most studies showed a
reduced risk of death from breast cancer in hormone replacement
users compared with nonusers, although in some studies the
reduction in risk was not statistically significant (Nanda et al,
2002).
There is evidence that hormone exposure might increase the
incidence of breast cancer (Beral, 2003). However, the effects of
hormones used at the time of diagnosis on breast cancer
development and on death from breast cancer are not necessarily
in the same direction. Comparison of the risk of death from breast
cancer for women exposed and not exposed to hormone therapy
measures the net effect of hormones on the development of breast
cancer and on death from breast cancer given hormone use or
nonuse at the time of diagnosis.
This study explored the relationship between survival after
breast cancer and exposure to oestrogen or oestrogen plus
progestin at or around the time of diagnosis, stratified by cancer
stage, and adjusting for other factors associated with survival.
METHODS
Design and setting
We conducted a retrospective, computer record-linkage, cohort
study among members of a large health maintenance organisation
(Kaiser Permanente Southern California, KPSC). The study was
approved by the KPSC Institutional Review Board.
Subjects and data
Using computerised KPSC Cancer Registry records, we identified
9572 patients diagnosed with their first invasive breast cancer
between 1 January 1993 and 31 December 1998, who had been
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scontinuously enrolled for 1 year prior to diagnosis (Figure 1).
Demographic characteristics and information about stage, tumour
size and grade, oestrogen receptor (ER) status, progesteron
receptor (PR) status, surgery status, and chemotherapy and
hormone therapy for first course of treatment was also obtained.
The KPSC Cancer Registry is a database that contains information
on patients who were diagnosed with cancer at KPSC hospitals or
who received at least part of their first course of treatment for
cancer at a KPSC hospital. The Registry reports to and follows the
requirements of the Surveillance, Epidemiology and End Results
(SEER) Program.
We then used KPSC computerised pharmacy data for the period
from 1 January 1992 to 31 December 2000 to classify patients
according to exposure to oestrogen or progestin during the study
period. The pharmacy database contains information on prescrip-
tions filled by health plan members at all KPSC pharmacies. We
included prescriptions for oral or transdermal oestrogen or oral
progestin alone and excluded prescriptions for drugs marketed as
oral contraceptives, as well as vaginal and injectable formulations
of oestrogen and progestin.
We ascertained vital status from 1 January 1993 through 31
December 2000 by linking data on our study subjects with
computer-stored data on deaths that is derived by probabilistic
matching of KPSC membership data with California death files. To
assure accuracy in designation of vital status, uncertain matches
defined by a linkage weight less than 10 were manually examined
and validated as true matches by visual inspection. Deaths with the
9th revision of International Classification of Disease (ICD) code
174 or the 10th revision of the ICD code C50 as the underlying
cause of death were considered deaths from breast cancer.
As we were interested in the impact of exposure to oestrogen
with or without progestin at or in the year prior to diagnosis, we
excluded from the analysis 579 patients exposed to oestrogen or
progestin after diagnosis; 515 past users of oestrogen with or
without progestin; and 100 users of progestin only at or in the year
prior to diagnosis (Figure 1). Finally, we excluded 942 patients
with TNM stage III or IV cancer due to their poorer prognosis
relative to earlier stage breast cancers. There remained 7436
patients with stage 0, I or II breast cancer. These included 1081
patients who exposed to oestrogen only and 1399 patients who
exposed to both oestrogen and progestin at or in the year prior to
diagnosis, and 4956 nonusers.
Analysis
As stage at diagnosis may be associated with exposure to oestrogen
and progestin and with survival, we stratified all analyses by stage.
We first performed a univariate analysis examining characteristics
of patients by hormone status. To test the statistical significance of
differences between groups, we used the w
2 test or Fisher’s exact
test for categorical variables and analysis of variance (ANOVA) for
continuous variables.
As the impact of oestrogen and progestin use might differ
between all-cause mortality and breast cancer mortality, both
outcomes were examined. Patient follow-up started from the breast
Excluded 
Excluded 
Excluded 
Excluded 
First invasive breast cancer  
Diagnosed 1993 – 1998 among 
members enrolled for at least 1 
year  (N = 9572) 
Exposed to Oestrogen or progestin after diagnosis 
N = 579 
Exposed to Oestrogen or progestin at least 1 
year prior to diagnosis but not at or in the year 
prior to diagnosis 
N = 515 
Exposed to progestin only at diagnosis or in the 
year prior to diagnosis 
N = 100 
 
Cancer stage III or IV at diagnosis 
N = 942 
 
Not exposed 
N = 4956 
Exposed to Oestrogen only at or in 
the year prior to diagnosis 
N = 1081 
 
Exposed to Oestrogen plus progestin  
at or in the year prior to diagnosis 
N = 1399 
Figure 1 Selection of study subjects.
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scancer diagnosis and ended with an outcome (either all-cause
death or breast cancer death) or when censoring occurred, on the
earliest of the following dates: health plan disenrollment; end of
study (31 December 2000); and nonbreast cancer death when the
outcome was breast cancer mortality. The Cox proportional
hazards model was used to estimate the hazard ratio for mortality
in relation to oestrogen and progestin exposure with nonhormone
users as the referent. Crude, age-adjusted, and age plus other
confounder-adjusted hazard ratios (HR) were calculated along
with their 95% confidence intervals (CI).
Adjusted survival curves were generated from the Cox models
by setting the covariates at their means. The covariates included in
these models were age at diagnosis, race/ethnicity, tumour size and
grade, ER status, surgery status, and chemotherapy and hormone
therapy for first course of treatment.
All analyses were conducted with SAS software (version 8.02 for
Windows, SAS Institute, Cary, NC, USA).
RESULTS
Among the 7436 eligible patients with breast cancer, 848 (11. 4%)
died during the study period. Of these deaths, 421 (5.7% of all
patients; 49.6% of all deaths) were attributed to breast cancer. Only
10 patients diagnosed with stage 0 died of breast cancer (Table 1)
and therefore further data are not shown for stage 0 patients. For
patients with stage I or II cancer, all-cause mortality was about 8%
in patients exposed to oestrogen plus progestin, 13–15% in
patients exposed to oestrogen only, and 18–19% in nonhormone
users. A similar pattern was found for breast cancer mortality
although the stage-specific breast cancer mortality rates differed
between stage I and II cancer patients.
Across stages I and II, exposure to oestrogen and progestin at
the time of diagnosis varied by age, race/ethnicity, and PR status
(Tables 2A and B). Oestrogen receptor status only differed by
oestrogen and progestin exposure status in stage II cancer patients
(P¼0.010). Follow-up time was longer among nonhormone users
for both stage I and II cancers (Po0.01). Among patients with
stage II cancer, nonhormone users presented with larger tumours
(P¼0.021); nonhormone users were more likely to present with
poorly differentiated tumours for both stages (Po0.001). In both
stage I and II patients, those who were exposed to hormones at the
time of or near breast cancer diagnosis were more likely to be
treated with hormones for their breast cancer after diagnosis
(Po0.001). During the time period in which patients in this
Table 1 Distribution of hormone use and death by stage at diagnosis
Stage Hormone exposure
No. of
patients
(N¼7436)
N (%) death
from all
causes
N (%) death
from breast
cancer
0 Oestrogen only 142 5 (3.5) 1 (0.7)
Oestrogen plus progestin 180 3 (1.7) 1 (0.6)
Neither 628 38 (6.1) 3 (0.5)
Total 950 46 (4.8) 5 (0.5)
I Oestrogen only 532 50 (14.7) 17 (3.2)
Oestrogen plus progestin 678 34 (8.5) 9 (1.3)
Neither 2259 244 (17.8) 73 (3.2)
Total 3469 328 (9.5) 99 (2.9)
II Oestrogen only 407 60 (12.7) 41 (10.1)
Oestrogen plus progestin 541 46 (8.3) 36 (6.7)
Neither 2069 368 (18.5) 240 (11.6)
Total 3017 474 (15.7) 317 (10.5)
Table 2 Characteristics of patients with (A) stage I and (B) stage II breast
cancer by hormone exposure status at the time of breast cancer diagnosis
(A)
Hormone exposure status
Oestrogen
only
(N¼532)
Oestrogen
plus
progestin
(N¼678)
Neither
(N¼2259) P
Mean (s.d.) age at
diagnosis in years
63.4 (9.6) 61.2 (8.0) 61.0 (13.9) o0.001
Mean (s.d.) month of
follow-up
50.2 (21.3) 50.1 (21.7) 54.0 (23.4) o0.001
Race/ethnicity (%) o0.001
African American 6.9 5.6 13.0
Asian 4.3 6.6 7.3
Latino 5.1 5.2 8.9
White 83.1 81.9 70.0
Other/unknown 0.6 0.7 0.8
Tumour size (%) 0.130
o1.0cm 38.7 40.0 37.5
X1.0cm 53.8 54.1 57.4
Unknown 7.5 5.9 5.1
Tumour grade (%) o0.001
Well differentiated 26.9 29.9 23.0
Moderately
differentiated
36.5 41.5 39.4
Poorly differentiated 18.4 16.8 21.4
Unknown 18.2 11.8 16.2
Oestrogen receptor (%) 0.417
Positive 66.4 65.8 62.7
Negative 14.5 14.3 16.1
Other/not done/
unknown
19.2 19.9 21.2
Progesterone receptor (%) o0.001
Positive 51.5 44.8 45.9
Negative 15.2 12.6 18.2
Other/not done/
unknown
33.3 42.6 35.9
Hormone therapy for breast
cancer treatment
a (%)
o0.001
Yes 58.3 56.6 46.8
No 41.7 43.4 53.2
Chemotherapy (%) o0.001
Yes 12.4 12.4 19.6
None/other/unknown 87.6 87.6 80.4
Surgery (%) 0.007
Lumpectomy 60.5 63.9 56.9
Mastectomy 38.7 35.4 41.5
None/other/unknown 0.8 0.7 1.6
(B)
Oestrogen
only
(N¼407)
Oestrogen
plus
progestin
(N¼541)
Neither
(N¼2069)
P
Mean (s.d.) age at
diagnosis in years
61.5 (9.3) 59.5 (7.9) 55.9 (14.5) o0.001
Mean (s.d.) month of
follow-up
47.1 (20.7) 47.9 (20.9) 50.3 (23.0) 0.007
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sstudy were diagnosed with breast cancer (1993–1998), the most
common hormone therapy for breast cancer treatment in use
was tamoxifen.
In both stage I and II patients, use of oestrogen plus progestin
at the time of or near breast cancer diagnosis significantly reduced
risk of all-cause mortality (Table 3A and B). After adjusting for
age at diagnosis, race/ethnicity, tumour size and grade, ER status,
surgery status, and chemotherapy and hormone therapy for breast
cancer treatment, the HR of all-cause mortality for oestrogen plus
progestin users vs nonusers were 0.69 (95% CI 0.48–0.99) for
stage I and 0.53 (95% CI 0.39–0.73) for stage II cancer patients.
Breast cancer mortality was reduced in stage II patients (HR 0.69,
95% CI 0.48–0.98). In stage I patients the risk reduction was
almost 50% but it was not statistically significant (HR 0.52, 95%
CI 0.26–1.04).
In both stage I and II patients, use of oestrogen alone at the time
of or near breast cancer diagnosis did not increase or decrease all-
cause or breast cancer mortality (Table 3A and B). After adjusting
for age at diagnosis, race/ethnicity, tumour size and grade, ER
status, surgery status, and chemotherapy and hormone therapy for
breast cancer treatment, the HR of all-cause mortality for
oestrogen only users vs nonusers were 1.04 (95% CI 0.77–1.42)
for stage I and 0.86 (95% CI 0.65–1.14) for stage II cancer patients.
The corresponding HR for breast cancer mortality were 1.23 (95%
CI 0.72–2.10) and 1.01 (95% CI 0.72–1.41).
Figure 2 shows that although the overall survival varied by
cancer stage, the improvement in survival among oestrogen plus
progestin users compared to nonusers remains consistent across
both cancer stages for both all-cause mortality and breast cancer
mortality.
We repeated the analyses excluding patients aged 55 years or
younger because these women might have been premenopausal.
The results were similar (data not shown).
DISCUSSION
This observational study of patients with breast cancer assessed
mortality for all causes and for breast cancer in relation to
oestrogen and progestin exposure at or in the year prior to breast
cancer diagnosis. Our results are mixed. They show a lower
mortality from all causes and from breast cancer in patients who
were diagnosed with breast cancer while exposed to oestrogen plus
Table 2 (Continued)
(B)
Hormone exposure status
Oestrogen
only
(N¼407)
Oestrogen
plus
progestin
(N¼541)
Neither
(N¼2069) P
Race/ethnicity (%) o0.001
African American 10.3 7.8 17.1
Asian 4.4 6.6 8.8
Latino 8.1 7.6 12.6
White 76.7 78.0 61.2
Other/unknown 0.5 0.0 0.3
Tumour size (%) 0.021
o2.0cm 37.4 35.9 29.9
2.0–4.9cm 53.8 53.8 59.5
X5.0cm 3.9 4.8 5.5
Unknown 4.9 5.5 5.1
Tumour grade 0.001
Well differentiated 11.8 15.0 9.8
Moderately
differentiated
38.3 40.5 37.9
Poorly differentiated 35.4 33.8 41.3
Unknown 14.5 10.7 11.0
Oestrogen receptor (%) 0.010
Positive 62.2 63.0 56.8
Negative 24.3 19.6 25.2
Other/not done/
unknown
13.5 17.4 18.0
Progesterone receptor (%) 0.028
Positive 47.2 43.4 42.2
Negative 24.8 20.0 24.2
Other/not done/
unknown
28.0 36.6 33.6
Hormone therapy for breast
cancer treatment
a (%)
o0.001
Yes 52.3 54.5 43.3
No/unknown 47.7 45.5 56.7
Chemotherapy (%) 0.172
Yes 60.0 61.6 64.3
None/other/unknown 40.0 38.4 35.7
Surgery (%) 0.167
Lumpectomy 41.8 41.0 37.4
Mastectomy 57.0 58.4 61.2
None/other/unknown 1.2 0.6 1.4
aDuring the study period, the most common hormone therapy in use for breast
cancer treatment was tamoxifen.
Table 3 Crude and adjusted hazard ratios (HR) and 95% confidence
intervals (CI) for patients with (A) stage I and (B) stage II breast cancer
according to hormone exposure status at the time of diagnosis
Adjustment Hormone exposure
All-cause
mortality HR
(95% CI)
Mortality from
breast cancer
HR (95% CI)
(A)
None Oestrogen only 0.95 (0.70–1.29) 1.10 (0.65–1.87)
Oestrogen plus progestin 0.51 (0.36–0.73) 0.46 (0.23–0.91)
Neither 1.00 (referent) 1.00 (referent)
Age only Oestrogen only 1.00 (0.74–1.36) 1.09 (0.64–1.85)
Oestrogen plus progestin 0.63 (0.44–0.90) 0.46 (0.23–0.92)
Neither 1.00 (referent) 1.00 (referent)
Multivariable
a Oestrogen only 1.04 (0.77–1.42) 1.23 (0.72–2.10)
Oestrogen plus progestin 0.69 (0.48–0.99) 0.52 (0.26–1.04)
Neither 1.00 (referent) 1.00 (referent)
(B)
None Oestrogen only 0.90 (0.68–1.18) 0.94 (0.67–1.31)
Oestrogen plus progestin 0.51 (0.38–0.69) 0.61 (0.43–0.87)
Neither 1.00 (referent) 1.00 (referent)
Age only Oestrogen only 0.82 (0.63–1.08) 0.96 (0.69–1.34)
Oestrogen plus progestin 0.49 (0.36–0.66) 0.62 (0.44–0.88)
Neither 1.00 (referent) 1.00 (referent)
Multivariable
a Oestrogen only 0.86 (0.65–1.14) 1.01 (0.72–1.41)
Oestrogen plus progestin 0.53 (0.39–0.73) 0.69 (0.48–0.98)
Neither 1.00 (referent) 1.00 (referent)
aAdjusted for age at diagnosis, race/ethnicity, tumour size and grade, oestrogen
receptor status, surgery status, and chemotherapy and hormone therapy for breast
cancer treatment.
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sprogestin. Neither all-cause nor breast cancer mortality was
decreased in the patients with breast cancer who were exposed
to oestrogen alone.
Several other studies have reported lower all-cause or breast
cancer mortality (Bergkvist et al, 1989; Hunt et al, 1990; Sturgeon
et al, 1995; Willis et al, 1996; Persson et al, 1996; Sellers et al, 1997;
Jernstrom et al, 1999; Schairer et al, 1999) in hormone users
compared with nonusers, while others have found no significant
differences in breast cancer mortality in hormone users compared
with nonusers (Hunt et al, 1990; Henderson et al, 1991; Grodstein
et al, 1997; Sourander et al, 1998). The Million Women Study
(MWS) reported an increased risk (RR 1.22, 95% CI 1.05–1.41) of
breast cancer mortality comparing current-users with never-users
(Beral, 2003). However, Bundred and Morris (2003) analysed
summary data from the MWS publication and showed that the
crude relative risk of breast cancer mortality was 0.725 for current
users vs never-users in the subgroup of women diagnosed with
breast cancer. Nevertheless, the lack of information on stage at
diagnosis and treatment makes the interpretation of these results
difficult. In 1995, the Nurses’ Health Study reported a relative risk
of death from breast cancer of 1.14 (95% CI 0.85–1.51) for current
hormone users and a risk of 1.45 (95% CI 1.01–2.09) for hormone
users of five or more years (Colditz et al, 1995). However, in 1997,
after 2-years of additional data and with adjustment of additional
covariates, the adjusted relative risk of mortality due to breast
cancer was 0.76 (95% CI 0.56–1.02) among current hormone users
compared with nonusers (Grodstein et al, 1997).
Few studies have directly assessed prognosis in breast cancer
that develops in women using hormones at the time of diagnosis
compared with those who were not using hormones at diagnosis.
The studies close in design to our study are those of Bergkvist et al,
Schairer et al, and Jernstrom et al, who also examined mortality in
women diagnosed with breast cancer in hormone users with
mortality in women diagnosed with breast cancer who were not
hormone users (Bergkvist et al, 1989; Schairer et al, 1999;
Jernstrom et al, 1999). Of these, Bergkvist et al’s study is closest
in design to ours in that breast cancer patients who were exposed
to oestrogen at different time periods in relation to diagnosis were
compared with breast cancer patients who had had no previous
oestrogen therapy. Oestrogen users had lower all-cause mortality,
0 1 22 43 64 86 07 28 49 6
Overall survival for stage I patients
0 1 22 43 64 86 07 28 49 6
0 12 24 36 48 60 72 84 96 0 12 24 36 48 60 72 84 96
Overall survival for stage II patients
Breast cancer survival for stage I patients  Breast cancer survival for stage II patients
1.0
0.9
0.8
0.7
1.0
0.9
0.8
0.7
1.0
0.9
0.8
0.7
1.0
0.9
0.8
0.7
E only
E + P
Never used
E only
E + P
Never used
E only
E + P
Never used
E only
E + P
Never used
Figure 2 Adjusted survival curves by hormone exposure status. Y-axis label, survival function estimate. X-axis label, months after breast cancer diagnosis.
All survival curves were adjusted for age at diagnosis, race/ethnicity, tumour size and grade, oestrogen receptor status, surgery status, and chemotherapy and
hormone therapy for breast cancer treatment.
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sbut the effect was more pronounced in recent users and users who
had been discontinued within a year prior to diagnosis (Bergkvist
et al, 1989).
Only a few studies have examined the association between
hormone type and breast cancer mortality. The results are mixed
(Bergkvist et al, 1989; Persson et al, 1996). Bergkvist reported a
greater reduction in breast cancer mortality in users of oestrogen
plus progestin than in user of oestrogen only (relative hazard 0.87
for oestrogen only users and 0.50 for oestrogen plus progestin).
Persson et al (1996) reported that women prescribed a fixed dose
oestrogen–progestin combination consisting of oestradiol and
levonorgestrel had smaller decrease in the relative risk of breast
cancer mortality than women prescribed oestrogen only. How-
ever, as noted above, in Persson’s study the standardised breast
cancer mortality ratios were lower than 1.0 in all hormone use
groups.
Several observational studies have reported that breast cancers
in hormone users are diagnosed earlier and have histologic and
other features that are associated with a better prognosis (Holli
et al, 1998; Sacchini et al, 2002; Daling et al, 2003; Pappo et al,
2004) However, results from the Women’s Health Initiative (WHI),
the only randomised controlled trial of hormone use, showed that
hormone users were diagnosed with larger tumours and more
likely to have positive lymph nodes (Chlebowski et al, 2003). The
study was underpowered to access the effect on grade, histology
and hormone receptor status. A recent systematic review of 25
studies that evaluated breast cancer risk factors and prognostic
indicators concluded that the WHI study is in contradiction to
most published observational studies (Antonie et al, 2004). Our
results also appear to contradict the WHI results. This discrepancy
might be due to biases in the observational studies including lack
of adjustment for important confounding factors. It might also be
due to the highly unrepresentative nature of WHI enrollees in
terms of age and time since menopause.
Understanding of the mechanisms underlying breast tumour
aggressiveness, prognosis and metastatic potential is incomplete.
Progesterone receptor is a prognostic marker in breast cancer. Two
functional progesterone receptor isoforms, PR-A and PR-B, have
been identified. Recent studies in animals have shown the ratio of
the isoforms affects tumour phenotype (Jacobsen et al, 2003, 2005)
and perhaps response to endocrine therapy (Sartorius et al, 2003;
Hopp et al, 2004; Wu et al, 2004). It is possible that exogenous
synthetic progestins alter the balance between PR-A and PR-B in
malignant breast tumours, thus affecting tumour aggressiveness.
This is admittedly highly speculative.
Our study has some strengths. First, the study involved a very
large number of cases of breast cancer, permitting estimation of
mortality stratified by cancer stage. Second, our study was able to
classify patients with breast cancer according to the use of
oestrogen alone or oestrogen plus progestin within each stage.
Third, our study was able to assess mortality risk in relation to
oestrogen and progestin exposure at the time or near breast cancer
diagnosis with large numbers. Finally, we were able to examine
both all-cause and breast cancer mortality.
Our study has several limitations. First, it is based on computer
record linkage. Patients were classified as exposed to oestrogen
and progestin based on having filled a prescription but it is
possible that they did not actually consume the drug. Also, for
health plan members who did not have drug coverage for
oestrogen and progestin (about 8%) and had to pay full member
rate, the information about exposure to hormones may be
incomplete. Second, in spite of the large number of breast cancer
cases, breast cancer mortality in stage 0 cancer patients was too
low to permit estimation of the risk of breast cancer mortality in
relation to hormone exposure in this group. Third, it is possible
that death due to causes other than breast cancer were assigned to
breast cancer because of a prior diagnosis of breast cancer. Fourth,
only 30 and 67% of deaths were attributable to breast cancer in
stage I and II patients, respectively. If hormone users were
healthier for reasons other than hormone use, all-cause mortality
would be biased due to the ‘healthy user’ and/or ‘healthy complier’
effect (Barrett-Connor, 1991; Petitti, 1994). Fifth, hormone users,
particularly if they were healthier, might have received additional
treatments beyond their first course of therapy. These treatments
were not available in the KPSC Cancer Registry and thus could not
be incorporated into the analysis. However, there is no reason to
expect these limitations would be different between oestrogen only
users and users of oestrogen plus progestin.
Given the limitations, the study results should be interpreted
cautiously. Other large databases of computer-stored prescription
information are available and could be used to attempt to replicate
or refute our observations.
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